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Epigenetic reprogramming plays a central 
role in the development of cloned embryos 
generated by somatic cell nuclear transfer 
(SCNT), and it is believed that aberrant 
reprogramming leads to the abnormal 
development of most cloned embryos. Recent 
studies show that trimethylation of H3K27 
(H3K27me3) contribute to the maintenance 
of embryonic stem (ES) cell pluripotency, 
since the differentiation genes are always 
occupied by nucleosomes trimethylated at 
H3K27, which represses gene expression. 
Here, we provide evidence that differential 
H3K27me3 modification exists between 
normal fertilization-produced blastocysts and 
SCNT-cloned blastocysts; H3K27me3 was 
specifically found in cells of the inner cell 
mass (ICM) of normal blastocysts, whereas 
there was no modification of H3K27me3 in 
the ICM of cloned blastocysts. Subsequently, 
we demonstrated that the 
differentiation-related genes, which are 
marked by H3K27me3 in ES cells, were 
expressed at significantly higher levels in 
cloned embryos than in normal embryos. The 
Polycomb repressive complex 2 (PRC2) 
component genes (Eed, Ezh2, and Suz12), 
which are responsible for the generation of 
H3K27me3, were expressed at lower levels in 
the cloned embryos. Our results suggest that 
reduced expression of PRC2 component 
genes in cloned embryos results in defective 
modification of H3K27me3 to the 
differentiation-related genes in the 
pluripotent ICM cells. This results in 
premature expression of developmental genes 
and death of somatic cloned embryos shortly 
after implantation. Taken together, these 
studies suggest that H3K27me3 might be an 
important epigenetic marker with which to 
evaluate the developmental potential of 
cloned embryos. 
 
Embryonic stem (ES) cells are derived from 
the inner cell mass (ICM) of a blastocyst. ES 
cells are pluripotent and can maintain 
self-renewal under appropriate culture 
conditions (1-3). Gene expression profiles of ES 
cells revealed that there is a core pluripotency 
regulatory circuitry, formed by Oct4, Sox2 and 
Nanog, which coordinated to maintain the 
transcriptional program required for the 
maintenance of ES cell pluripotency (4). Results 
from recent studies have indicated that ES cells 
possess a bivalent chromatin structure, which 
has been suggested to be essential for 
maintaining their self-renewal and pluripotency 
characteristics. The bivalent chromatin domains 
of ES cells consisted of large regions of H3K27 
methylation and smaller regions of H3K4 
methylation (5). Trimethylation of H3K27 is 
associated with the activity of Polycomb 
repressive complex 2 (PRC2); and recent studies 
have indicated that PRC2 specifically targets 
developmental genes, which are marked by 
H3K27me3, to maintain ES cell pluripotency by 
repressing these genes expression (6-12). 
Somatic cell nuclear transfer (SCNT) 
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represents a remarkable process in which the 
differentiated somatic cell genome can be 
converted into a totipotent or at least a 
pluripotent state (13-16). However, the 
efficiency of cloning is extremely low, as less 
than 5% of cloned embryos could develop into 
live animals. Aberrant epigenetic 
reprogramming has been suggested as the cause 
of this inefficiency; however, little is known 
about the chromatin modifications in cloned 
embryos, except that abnormal DNA 
methylation has been observed (17,18). As 
previously mentioned, histone methylation 
regulates gene expression and silencing in 
pluripotent stem cells. It remains unknown if 
histone methylation could be correctly 
reprogrammed through SCNT and whether 
aberrant reprogramming of histone methylation 
could result in abnormal gene expression that 
ultimately leads to the death of most SCNT 
embryos soon after implantation.   
Here, we provide evidence demonstrating that 
loss of H3K27me3 mark in ICM cells was 
widely observed in SCNT-produced blastocysts. 
Such defective reprogramming of H3K27me3 in 
somatic clones was caused by inadequate 
expression of PRC2 component genes, 
particular Ezh2; which in turn drove the 
premature expression of differentiation genes 
and caused early death of cloned embryos. 
These results suggest that H3K27me3 may be an 
important epigenetic marker representing the 
developmental potential of cloned embryos, and 
that treatments that restore the function of the 
PRC2 components in clones may increase the 
survival of cloned embryos.   
 
Experimental Procedures 
Collection of MII-arrested Oocytes and the 
Preparation of Cumulus Cells The specific 
pathogen-free (SPF) Female B6D2F1 
(C57BL/6×DBA/2) mice (8–10 weeks old) were 
superovulated by the sequential injection of 7 i.u. 
each of serum gonadotropin (PMSG) and human 
chorionic gonadotropin (hCG) (Sigma). 
Metaphase II (MII) oocytes and the surrounding 
cumulus cells were collected for nuclear transfer. 
All studies adhered to procedures consistent 
with the National Institute of Biological 
Sciences Guide for the care and use of 
laboratory animals. 
 
Somatic Cell Nuclear Transfer (SCNT) To 
generate diploid cloned constructs by SCNT, 
spindle-chromosomes complexes (SCC) of 
MII-arrested oocytes were first removed. After 
SCC removal, oocytes were kept in CZBG 
medium until injection(19,20). Cumulus cell 
nucleus was separated and injected into the 
enucleated oocyte using a Piezo-drill 
micromanipulator. After injection of the 
cumulus nucleus, the cloned constructs were 
allowed to recover for several minutes before 
transfer back to CZBG medium. Reconstructed 
oocytes were cultured in CZBG medium for 
approximately 1–3 h before activation. Then 
activation was achieved by 6 h of culture of 
cloned constructs in calcium-free CZBG 
medium containing 10 mM of Strontium 
chloride and 5 μg/ml of cytochalasin B (CB). 
Activated constructs were thoroughly washed 
and cultured in KSOM medium (Chemicon). 
 
Collection of Fertilized Embryos and Cloned 
Embryos  For studies requiring zygotes, 
successfully mated B6D2F1 female mice were 
sacrificed 20 h post-hCG and zygotes were 
collected in M2 medium (Sigma) and cultured in 
KSOM medium. This medium supports efficient 
development of cumulus cell-cloned constructs 
as well as control fertilized embryos. Finally, the 
cloned embryos were collected at 26 hours 
(2-cell), 42 hours (4-cell), 51 hours (8-cell), 69 
hours (morula), and 91 hours (blastocyst) post 
Strontium chloride treatment as well as control 
fertilized embryos: 24 hours (2-cell), 40 hours 
(4-cell), 45 hours (8-cell), 64 hours (morula), 
and 86 hours (blastocyst) post hCG injection. To 
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collect late stage blastocysts, the blastocysts 
were culture one more day in the KSOM 
medium. To investigate the histone 
modifications in early stage embryos, the cloned 
constructs and intracytoplasmic sperm injection 
(ICSI)-produced embryos used as control were 
collected as previously described (21).   
 
Immunofluorescent Detection of H3K27me3, 
H3K4me3, Nanog, Oct4, Cdx2 and Ezh2 All 
samples were fixed in 4% paraformaldehyde for 
30 min followed by permeabilization in PBS 
containing 0.5% Triton X-100 for 15 min. After 
blocking and incubated with rabbit polyclonal 
antibodies: anti-H3K27me3 (Upstate; diluted 
1:100) or anti-H3K4me3 (Abcam; diluted 1:200) 
for 1 h, samples were incubated with the Alexa 
Fluor 488 goat anti-rabbit IgG conjugate 
(Molecular Probes; diluted 1:1000) for 1 h. To 
visualize the pluripotent cells and trophectoderm 
cells, the samples were incubated with 
anti-Nanog polyclonal antibody (Cosmobio; 
diluted 1:500) or anti-Oct3/4 monoclonal 
antibody (Santa Cruz; diluted 1:500) and 
anti-CDX-2 monoclonal antibody (BioGenex; 
diluted 1:50) for 1 h and secondary antibody 
conjugated to Alexa 594 goat anti-rabbit IgG 
conjugate (Molecular Probes; diluted 1:1000). 
Mouse monoclonal anti-Ezh2 antibody (Cell 
Signaling Technology, diluted 1:100) was used 
to detect Ezh2 in embryos. 
 
Real-time RT-PCR  RNA was extracted from 
fertilized embryos and cloned embryos using the 
PicoPure RNA Isolation Kit (ARCTURUS) and 
was reverse-transcribed using the SuperScript 
III First-Strand Synthesis System for RT-PCR 
(18080-051, Invitrogen). Real-time PCR was 
performed on an ABI Prism 7500 using SYBR 
Green Pre-mix (Takara). Primer pairs that are 
specific for PRC2, pluripotent genes and 
developmental genes were listed in the Table S2. 
Gadph was used as control for the quality and 
amount of the reverse-transcribed RNA. 
 
Western Blot Whole cell lysates from embryos 
(260 embryos each: SCNT and fertilized 
blastocyst) were subjected to immunoblotting 
with rabbit polyclonal anti-H3K27 antibody 
(07449, Upstate), mouse monoclonal 
anti-α-tubulin (T6199 ， Sigma) and mouse 
monoclonal anti-Oct3/4 antibody (SC-5279, 
Santa Cruz). The secondary antibodies were 
ECL rabbit IgG (NA934, GE) and ECL Mouse 
IgG (NA931, GE). For detection of Ezh2 
(mouse monoclonal anti-EZH2 antibody, AC22, 
Cell Signaling Technology), lysates from 240 
embryos (SCNT and control blastocysts) were 
subjected to western blotting. 
 
Statistical Analysis Values of real time PCR are 
expressed as medians or means (with 95% 
confidence intervals). Correlations between 
assays were evaluated by linear regression 
(SPSS version 11.0, SPSS Inc., Chicago, IL, 
USA).  P values <0.05 were considered 
significant. 
 
 
RESULTS 
Aberrant Reprogramming of H3K27me3 in the 
Somatic Cell Cloned Blastocysts 
To determine if the SCNT produced embryos 
could recapitulate the ES-like bivalent 
chromatin structure at blastocyst stage, 
modification of H3K4 me3 and H3K27me3 in 
both normal fertilized and SCNT cloned 
embryos during pre-implantation development 
was extensively investigated. As shown in 
Figure 1, H3K4 me3 was evenly distributed in 
the nucleus of normal fertilization-produced 
embryos through the two-cell to blastocyst stage 
(Figure 1, left panel). Compared with normal 
embryos, the pattern of H3K4 me3 modification 
in somatic cloned embryos showed no 
significant difference, except that the intensity 
of H3K4 me3 fluorescence was much higher in 
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the cloned embryos between the 2-cell and 
8-cell stage (Figure 1, right panel). However, the 
intensity exhibited no difference at the morula 
and blastocyst stage; all the cells were marked 
with H3K4 me3 modification.   
Next, modification of H3K27me3 was 
compared in somatic cloned embryos and 
fertilization-produced embryos. In striking 
contrast to H3K4 me3, there were dramatic 
changes in H3K27me3 during early 
development in both normal and cloned 
embryos (Figure 2). The nuclei of normal 
embryos between the 2- and 8-cell stages were 
positively marked with H3K27me3, while the 
H3K27me3 mark disappeared when the 
embryos reached morulae stage. These results 
indicated that global demethylation of 
H3K27me3 occurred at this specific stage, 
which is inconsistent with a previous report (22). 
This result might be caused by the embryos 
collected at different time point from the 
previous report.  Subsequently, only a small 
proportion of cells were found positively 
re-marked with H3K27me3 at the blastocyst 
stage and asymmetric H3K27me3 marking 
appeared, which may specify cells with different 
developmental potentials (Figure 2, left panel). 
Compared with normal embryos, there was no 
marked difference in the pattern of H3K27me3 
modification in somatic cell cloned embryos 
until the morulae stage. As in control embryos, 
global demethylation of H3K27me3 occurred at 
morula stage and no H3K27me3 remained in the 
cloned embryos. However, there was no 
evidence of positive marking of H3K27me3 in a 
small population of cells, as had been observed 
in the cloned blastocysts (Figure 2, right panel; 
Table 1). It became important to determine if the 
small population of cells positively marked with 
H3K27me3 were different from the negative 
cells in the normal embryos, as this 
sub-population may provide insight into the 
inefficient development of somatic cloned 
embryos. To exclude the effects of culture, 
ICSI-produced embryos were cultured in vitro 
and collected to examine the H3K27me3 
modification in parallel with normal embryos. 
As shown in Figure S1, no difference was 
observed in H3K27me3 marking in 
ICSI-produced embryos as compared with 
fertilization-derived embryos cultured in vitro. 
 
Defective Marking of H3K27me3 to the ICM 
Cells of Cloned Blastocysts 
Based on the findings presented above, 
experiments were performed to define the 
characteristics of the small population of cells 
positively marked with H3K27me3 in normal 
blastocysts. ICM cells are pluripotent cells, 
which can be maintained in a pluripotent state in 
vitro as embryonic stem (ES) cells. Three 
important transcriptional factors, Oct4, Nanog 
and Sox2, are specifically expressed in the ICM 
cells and are important for maintenance of 
pluripotency(23-26). In the present study, 
expression of Nanog and Oct4 was investigated 
in both types of embryos to distinguish the ICM 
cells from the trophoblast cells in which Cdx2 is 
highly expressed (Figure S2). As shown in 
Figure 3, in the control embryos, the small 
population of cells that stained positively for 
H3K27me3 were also stained for Nanog, which 
indicated that the ICM cells of normal embryos 
specifically marked with H3K27me3 were 
pluripotent (Figure 3, upper panel). Similarly, a 
small population of cells were found positively 
stained for Nanog in somatic cloned embryos, 
however, these Nanog-positive cells were not 
marked with H3K27me3 (Figure 3, lower panel). 
ICSI-produced blastocysts were collected and 
the triple staining results indicated that the 
Nanog positive cells were specifically marked 
with H3K27me3, which is similar to 
fertilization-produced blastocysts (Figure S3). 
Similarly, Oct4, another important transcription 
factor expressed in pluripotent cells, was 
examined in both fertilization- and 
SCNT-produced embryos. As shown in Figure 4, 
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Oct4 positive cells were detected in both kinds 
of embryos, but the intensity of Oct4 staining 
was weaker in clones. In addition, there was a 
dramatic difference in H3K27me3 staining, 
which is similar to the observations we 
described above. Western blotting was further 
performed to confirm the immunofluorescence 
staining results. Somatic cloned blastocysts and 
the normal fertilization-produced blastocysts 
(260 each) were collected for SDS-PAGE and 
western blotting analysis. As shown in Figure 
3B, H3K27me3 could be clearly detected in the 
normal blastocyst lysates lane, whereas no 
H3K27me3 could be detected in the somatic 
cloned blastocysts lane. Similar to previous 
report, Oct4 expression was much weaker in the 
somatic clones than the normal embryos. 
α-tubulin was used as a control and there was no 
difference in its expression between cloned and 
normal embryos. These results strongly 
suggested that the ICM cells in somatic cloned 
embryos are defective in maintaining 
pluripotency, since modification of H3K27me3 
in ES cells has been associated with the 
repression of differentiation genes. 
 
Defective Marking of H3K27me3 Leads to 
Up-regulation of Developmental Gene 
Expression in Cloned Embryos 
To further investigate if the defective marking of 
H3K27me3 in the somatic cloned embryos 
results in aberrant expression of differentiation 
genes, quantitative real time RT-PCR was 
performed to evaluate the expression of key 
genes whose promoters have been previously 
shown to be occupied by H3K27me3 in ES cells 
(12). As shown in Figures 5A and 5B, the 
expression of the key developmental genes 
Hind1, HoxB1, and HoxB4, which mediate 
germ layer differentiation, was significantly 
elevated in somatic cloned blastocysts. The 
expression of pluripotent genes Nanog, Sox2 
and Oct4 was simultaneously determined 
(Figure 5C). There was no difference in the 
expression of Nanog and Sox2 between somatic 
cloned blastocysts and fertilization-produced 
blastocysts. However, Oct4 expression was 
significantly reduced in somatic clones, which is 
consistent with previous studies (27,28). Our 
results indicated that defective marking of 
H3K27me3 is associated with the up-regulation 
of developmental genes, which may promote 
premature differentiation of the somatic cloned 
embryos.  
 
Aberrant Expression of PRC2 Genes Caused 
Defective Marking of H3K27me3 to the ICM 
Cells of Cloned Blastocysts 
Trimethylation of H3K27 is catalyzed by PRC2, 
which consists of Eed, Ezh2 and Suz12. To 
investigate if the defective marking of 
H3K27me3 in the ICM cells of somatic cloned 
embryos was caused by aberrant expression of 
PRC2 components, quantitative RT-PCR was 
performed to evaluate the expression levels of 
PRC2 genes in cloned morula and blastocysts. 
As shown in Figure 5D, expression of Eed, 
Ezh2 and Suz12 was significantly lower in the 
somatic cloned morula than in normal embryos 
at the same developmental stage. Similarly, 
expression of these three genes was decreased in 
cloned blastocysts as compared to normal 
blastocysts (Figure 5E). Immunofluorescence 
staining and western blotting were performed to 
investigate the expression of Ezh2 protein in 
both normal and cloned blastocysts. As shown 
in Figure 6A, localization of Ezh2 in the nucleus 
was detected in the pre-implantation control 
embryos, and the intensity of Ezh2 staining was 
higher in a small proportion of cells at the 
blastocyst stage (Figure 6A, left panel). 
Similarly, we have found that the small cell 
population of pluripotent ICM cells is Oct4 
positive in normal embryos (Figure S4). In 
contrast, there were dramatic differences 
between Ezh2 staining in cloned embryos at the 
blastocyst stage and in control embryos; Ezh2 
staining was very weak in the cloned blastocysts 
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(Figure 6A, right panel). To verify the 
immunofluorescence staining results, western 
blotting was performed. Similar to the 
H3K27me3 results presented above, there was 
no obvious Ezh2 protein detected using western 
blotting in the lysates generated from 240 
cloned blastocysts. In contrast, a very specific 
band of Ezh2 was detected using the same 
amount of normal blastocyst lysates (Figure 6B). 
These results suggested that defective marking 
of H3K27me3 in the ICM cells in the somatic 
cloned blastocysts was directly caused by the 
down-regulation of PRC2 components in cloned 
embryos. PRC2 components are essential for 
embryonic development, and it has been 
previously demonstrated that knockout of any of 
the three genes is embryonically lethal (29-31). 
It has been shown that knockout of Ezh2 caused 
depletion of H3K27me3 modification in ICM 
cells, which is similar to the phenomenon that 
we observed in this study. The Ezh2 mutant 
embryos died soon after implantation, and the 
dead embryos were found to contain 
predominantly mesodermic tissue. Our gene 
expression data has indicated that the 
developmental genes directing mesoderm 
differentiation were highly expressed in the 
somatic cloned embryos. Loss of cloned 
embryos right after implantation has been 
confirmed in previous studies, and all the data 
indicated that defective H3K27me3 marking in 
the ICM cells of somatic cloned embryos may 
contribute to the premature death of somatic 
clones. 
 
DISCUSSION 
Overall, these results suggest that inadequate 
expression of PRC2 components, Eed, Ezh2 and 
Suz12, particular Ezh2, leads to inadequate 
methylation of H3K27 in ICM cells of somatic 
cloned embryos, and this results in greater 
expression of developmental genes that induce 
premature differentiation and death of clones. To 
our knowledge, this is the first time that these 
differences have been distinguished between 
SCNT- and fertilization-produced blastocysts. 
These studies suggest that H3K27me3 might be 
an important epigenetic marker with which to 
evaluate the developmental potential of cloned 
embryos, and that treatments that enhance 
H3K27me3 in cloned embryos might be an 
effective strategy to improve the efficiency of 
cloning. 
ICM cells are the ES cell counterparts in vivo 
and a similar pluripotency regulatory network 
might be employed to precisely regulate the 
determination of cell fate during embryonic 
development. Two master pluripotency 
regulators, Oct4 and Nanog, are essential for 
early embryonic survival and mutation of either 
results in early embryonic lethality (23,25,26). 
In addition, epigenetic modifications also 
contribute to the maintenance of the 
pluripotency of ICM cells. It has been 
previously proven that PRC2 component genes 
including Ezh2, Eed and Suz12 function in early 
embryonic development (29-31). Mutation of 
each of these genes during early development 
will result in loss of H3K27me3 mark in the 
ICM cells of mutant blastocysts (29). 
Subsequently, the mutant embryos will 
differentiate prematurely, which will cause early 
embryonic death shortly after implantation. 
These data implicated that the maintenance of 
pluripotency of ICM cells in the blastocysts 
requires precise expression of both master 
pluripotency-regulating genes and PRC2 genes. 
The efficiency of cloning has remained 
extremely low since the first SCNT-cloned 
animal was generated a decade ago, and the 
cause of this inefficiency is poorly 
understood(32,33). Extensive efforts have been 
undertaken to improve the efficiency of cloning, 
such as treating the cloned embryos with histone 
deacetylase inhibitors to alter the global histone 
acetylation during development. However, even 
though the cloned embryos developed to the 
blastocyst stage with higher efficiency, the 
  6
 
b
y
 
o
n
 
J
u
l
y
 
2
3
,
 
2
0
0
9
 
w
w
w
.
j
b
c
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
  
late-stage development was not significantly 
improved (21,34-36). Collectively, the data 
indicate that most somatic clones died soon after 
implantation, which is similar to the phenomena 
observed in pluripotency master regulators or 
PRC2 components mutant embryos.   
Overall, these data suggested that the somatic 
clones are epigenetically defective at the 
blastocyst stage. Our results further 
demonstrated that loss of the H3K27me3 mark 
in the ICM cells of most cloned embryos will 
cause premature expression of the genes that 
should be repressed by the activity of PRC2, 
which results in early embryonic death that 
phenocopies PRC2 mutants. 
Up to date, no non-human primates have ever 
been successfully cloned by SCNT(37); 
moreover, derivation of individual 
patient-specific autologous NT-ES cells has not 
been achieved(38) and it will deserve to further 
investigate if cloned human blastocysts posses 
the similar H3K27me3 defects as observed in 
the mouse clones.   
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H3K27 trimethylation, H3K27me3; intracytoplasmic sperm injection, ICSI. 
 
FIGURE LEGENDS 
 
Figure 1 Modification of H3K4me3 in pre-implantation embryos. Left panel: Fertilization produced 
embryos at 2, 4, 8-cell, morula and blastocyst stage; scale bar, 10 μm. Right panel: Cumulus cell 
SCNT produced embryos at 2, 4, 8-cell, morula and blastocyst stage; scale bar, 10 μm. 
 
Figure 2 Modification of H3K27me3 in pre-implantation embryos. Left panel: Fertilization produced 
embryos at 2, 4, 8-cell, morula and blastocyst stage, positive staining of H3K27me3 could be 
observed in 2-8 cell stage. Global demethylation of H3K27 occurred at morula stage. A small 
proportion of cells were re-marked with H3K27me3 at blastocyst stage. Scale bar, 10 μm. Right panel: 
Cumulus cell SCNT produced embryos at 2, 4, 8-cell, morula and blastocyst stage, positive staining of 
H3K27me3 could be observed in 2-8 cell stage. Global demethylation of H3K27 occurred at morula 
stage. But no H3K27me3 mark could be detected at blastocyst stage. Scale bar, 10 μm.
 
Figure 3 Co-localization of H3K27me3 with Nanog in the ICM of Fertilization-produced blastocyst. 
(A), Upper panel: A fertilization-produced blastocyst, co-localization of H3K27me3 with Nanog 
staining could be detected in the ICM cells; scale bar, 10 μm. Lower Panel: A cumulus 
SCNT-produced blastocyst, a small proportion of cells could be stained by Nanog, but H3K27me3 
mark is absent; 10 μm. (B): Western blotting, left lane: Fertilization-produced blastocysts showed 
positive H3K27me3, Oct4; right lane: Cumulus SCNT-produced blastocysts showed weaker Oct4 and 
non-H3K27me3. α-tubulin was used as control and showed no difference between cloned and normal 
blastocysts. 
 
Figure 4 Co-localization of H3K27me3 with Oct4 in the ICM of blastocyst. Upper panel: A 
fertilization-produced blastocyst, co-localization of H3K27me3 with Oct4 staining could be detected 
in the ICM cells; scale bar, 10 μm. Lower Panel: A cumulus SCNT-produced blastocyst, a small 
proportion of cells could be stained by Oct4, but H3K27me3 mark is absent; 10 μm. 
 
 
Figure 5 Quantitative real time RT-PCR analysis of PRC2, pluripotent and developmental genes 
expression. (A), (B): The differentiation-related genes (Cdx2, GATA6, HAND1, HoxB1, HoxB4), 
were up-regulated significantly in cloned embryos compared with normal embryos at blastocyst and 
late blastocyst stages (NT-B: Cumulus cell SCNT-produced day 3.5 blastocysts; F-B: 
fertilization-produced day 3.5 blastocysts; L-NT-B: Cumulus cell SCNT-produced day 4.5 blastocysts; 
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L-F-B: Fertilization-produced day 4.5 blastocysts). (C): Expression comparison of pluripotent genes 
of embryos at the blastocyst stage. SCNT-produced embryos showed similar expression level of 
Nanog and Sox2 compared with fertilization-produced embryos, however Oct4 expression was 
significantly reduced in clones. (D), (E): The PRC2 components (Eed, Ezh2, and Suz12) responsible 
for H3K27me3 were down-regulated in cloned embryos, especially at the morula stage. (NT-M: 
SCNT-produced day 2.5 morulae; F-M: Fertilization-produced day 2.5 morulae; * represents P<0.05; 
** represents P<0.01; *** represents P<0.001). 
 
Figure 6 Detection of Ezh2 Expression in Pre-implantation Normal and Cloned Embryos. (A), Left 
panel: Expression of Ezh2 in fertilization-produced normal embryos at 2-, 4-, 8-cell, morula and 
blastocyst stages detected by immunofluorescence staining, enhanced Ezh2 staining in a small 
proportion of cells could be detected at the blastocyst stage; scale bar, 10 μm. Right panel: Expression 
of Ezh2 in SCNT-produced cloned embryos at 2-, 4-, 8-cell, morula and blastocyst stages detected by 
immunofluorescence staining, no obvious Ezh2 staining could be observed in cloned blastocysts; 
scale bar, 10 μm. (B): Western blotting, right lane: Fertilization-produced blastocysts showed positive 
Ezh2, H3K27me3; left lane: Cumulus SCNT-produced blastocysts showed weaker Ezh2 and 
non-H3K27me3. α-tubulin was used as control and showed no difference between cloned and normal 
blastocysts. 
 
Table 1. H3K27me3 positive blastocysts derived from fertilization and SCNT 
 
Embryo type  No. Day 3.5 blastocysts examined  No. H3K27me3 positive blastocysts (%) 
F-blastocyst 34  34  (100) 
SCNT-blastocyst 42  1  (2) 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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